Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
暂无分享,去创建一个
P. Zhao | W. Fang | Q. Fu | Xiaomeng Dai | Z. Tong | Xuanwen Bao | Yi Zheng | Lulu Liu | Xudong Zhu | Hangyu Zhang